Literature DB >> 7584924

Endothelium-dependent responses in hypertension.

P M Vanhoutte1, C M Boulanger.   

Abstract

The endothelium controls the tone of the underlying vascular smooth muscle by releasing relaxing factors. These include prostacyclin, nitric oxide (NO), and endothelium-derived hyperpolarizing factor (EDHF). In certain types of hypertension, endothelium-dependent relaxations are curtailed, because of a reduced production and/or action of endothelium-derived NO and EDHF. In the spontaneously hypertensive rat, endothelium-dependent relaxations are reduced, because of the endothelium-dependent production of vasoconstrictor prostanoids (endoperoxides and, in some cases, thromboxane A2). These prostanoids may be produced in the vascular smooth muscle cells rather than in the endothelium. The endothelial dysfunction observed in hypertensive blood vessels is likely to be a consequence rather than a cause of the disease process.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7584924     DOI: 10.1291/hypres.18.87

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  17 in total

Review 1.  Endothelium-dependent contractions in hypertension.

Authors:  Paul M Vanhoutte; Michel Feletou; Stefano Taddei
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

2.  Chronic social isolation in the prairie vole induces endothelial dysfunction: implications for depression and cardiovascular disease.

Authors:  Jacob D Peuler; Melissa-Ann L Scotti; Laura E Phelps; Neal McNeal; Angela J Grippo
Journal:  Physiol Behav       Date:  2012-03-26

3.  Asymmetric dimethylarginine inhibits HSP90 activity in pulmonary arterial endothelial cells: role of mitochondrial dysfunction.

Authors:  Neetu Sud; Sandra M Wells; Shruti Sharma; Dean A Wiseman; Jason Wilham; Stephen M Black
Journal:  Am J Physiol Cell Physiol       Date:  2008-04-02       Impact factor: 4.249

4.  Increased aortic stiffness elevates pulse and mean pressure and compromises endothelial function in Wistar rats.

Authors:  Xiaomei Guo; Xiao Lu; Junrong Yang; Ghassan S Kassab
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-07-18       Impact factor: 4.733

5.  Renoprotection, renin inhibition, and blood pressure control: the impact of aliskiren on integrated blood pressure control.

Authors:  Haroon-Ur Rashid
Journal:  Integr Blood Press Control       Date:  2010-10-05

6.  The antihypertensive effect of ethyl acetate extract from red raspberry fruit in hypertensive rats.

Authors:  Han Jia; Ji Wen Liu; Halmurat Ufur; Geng Sheng He; Hai Liqian; Peipei Chen
Journal:  Pharmacogn Mag       Date:  2011-01       Impact factor: 1.085

7.  Hypertension is associated with marked alterations in sphingolipid biology: a potential role for ceramide.

Authors:  Léon J A Spijkers; Rob F P van den Akker; Ben J A Janssen; Jacques J Debets; Jo G R De Mey; Erik S G Stroes; Bert-Jan H van den Born; Dayanjan S Wijesinghe; Charles E Chalfant; Luke MacAleese; Gert B Eijkel; Ron M A Heeren; Astrid E Alewijnse; Stephan L M Peters
Journal:  PLoS One       Date:  2011-07-19       Impact factor: 3.240

8.  Linking regulation of nitric oxide to endothelin-1: The Yin and Yang of vascular tone in the atherosclerotic plaque.

Authors:  Rajat M Gupta; Peter Libby; Matthias Barton
Journal:  Atherosclerosis       Date:  2019-11-14       Impact factor: 6.847

9.  Protein engineering to develop a redox insensitive endothelial nitric oxide synthase.

Authors:  Ruslan Rafikov; Sanjiv Kumar; Saurabh Aggarwal; Daniel Pardo; Fabio V Fonseca; Jessica Ransom; Olga Rafikova; Qiumei Chen; Matthew L Springer; Stephen M Black
Journal:  Redox Biol       Date:  2014-01-14       Impact factor: 11.799

10.  Studies on two polyherbal formulations (ZPTO and ZTO) for comparison of their antidyslipidemic, antihypertensive and endothelial modulating activities.

Authors:  Nauman Aziz; Malik Hassan Mehmood; Anwarul-Hassan Gilani
Journal:  BMC Complement Altern Med       Date:  2013-12-26       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.